Parikh, Aparna R. http://orcid.org/0000-0002-5245-7841
Szabolcs, Annamaria
Allen, Jill N.
Clark, Jeffrey W.
Wo, Jennifer Y.
Raabe, Michael
Thel, Hannah
Hoyos, David
Mehta, Arnav
Arshad, Sanya
Lieb, David J.
Drapek, Lorraine C.
Blaszkowsky, Lawrence S.
Giantonio, Bruce J.
Weekes, Colin D.
Zhu, Andrew X.
Goyal, Lipika
Nipp, Ryan D.
Dubois, Jon S.
Van Seventer, Emily E.
Foreman, Bronwen E.
Matlack, Lauren E.
Ly, Leilana
Meurer, Jessica A.
Hacohen, Nir http://orcid.org/0000-0002-2349-2656
Ryan, David P.
Yeap, Beow Y.
Corcoran, Ryan B.
Greenbaum, Benjamin D.
Ting, David T. http://orcid.org/0000-0002-3261-2322
Hong, Theodore S. http://orcid.org/0000-0001-8481-6581
Funding for this research was provided by:
EIF | Stand Up To Cancer
Lustgarten Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50CA127003, R01CA240924, U01CA228963, U01CA228963, R01CA240924)
Article History
Received: 12 August 2020
Accepted: 15 September 2021
First Online: 18 November 2021
Competing interests
: A.R.P is a consultant and/or advisory board member for Eli Lilly, Natera, Checkmate Pharmaceuticals, Inivata and Pfizer; holds equity in C2I; serves on the DSMC for Roche; and has research funding from PureTech, PMV Pharmaceuticals, Plexxicon, Takeda, BMS, Novartis, Genentech, Guardant, Array and Eli Lilly. J.W.C. is an author for McGraw Hill and UpToDate. A.M. is a consultant and/or advisory board member for Third Rock Ventures, Asher Biotherapeutics, Abata Therapeutics, Rheos Medicines and Checkmate Pharmaceuticals; and holds equity in Asher Biotherapeutics and Abata Therapeutics, which are not related to this work. C.D.W. is a consultant and/or advisory board member for Ipsen, Bristol Myers Squibb and Eli Lilly; and receives research funding from Deciphera, EMD Serono, Ability Pharmaceuticals, Actuate Therapeutics and Novartis. A.X.Z. is a consultant and/or advisory board member for AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Eli Lilly, Exelixis, Merck, Novartis and Roche–Genentech; and received research funding from Bayer, Bristol Myers Squibb, Eli Lilly, Merck and Novartis. L.G. is a consultant and/or advisory board member for Alentis, AstraZeneca, Exelixis, Sirtex, Genetech, Genentech, H3 Biomedicine, Incyte, QED Therapeutics, Servier and Taiho; and has research funding from Adaptimmune, Bayer, Bristol Myers Squibb, Eisai, Leap Therapeutics, Loxo Oncology, MacroGenics, Merck, Novartis, NuCana, Relay Therapeutics, Genentech, H3 Biomedicine, Incyte, QED Therapeutics, Servier and Taiho. N.H. is an advisor and equity holder for Related Sciences, holds equity in BioNTech and receives research funding from Bristol Meyers Squibb. D.P.R. is a consultant and/or advisory board member for MPM Capital, Gritstone Oncology, Oncorus, Maverick Therapeutics, 28/7 Therapeutics, Thrive–Exact Sciences; has equity in MPM Capital, Acworth Pharmaceuticals and Thrive–Exact Sciences; is a legal consultant for Boeringer Ingelheim; and serves as an author for Johns Hopkins University Press, UpToDate and McGraw Hill. R.B.C. is a consultant and/or advisory board member for AbbVie, Amgen, Array Biopharma–Pfizer, Asana BioSciences, Astex Pharmaceuticals, AstraZeneca, Avidity Biosciences, BMS, C4 Therapeutics, Chugai, Elicio, Erasca, Fog Pharma, Genentech, Guardant Health, Ipsen, Kinnate Biopharma, Loxo, Merrimack, Mirati Therapeutics, Natera, Navire, N-of-One–Qiagen, Novartis, nRichDx, Remix Therapeutics, Revolution Medicines, Roche, Roivant, Shionogi, Shire, Spectrum Pharmaceuticals, Symphogen, Tango Therapeutics, Taiho, Warp Drive Bio and Zikani Therapeutics; holds equity in Avidity Biosciences, C4 Therapeutics, Erasca, Kinnate Biopharma, nRichDx, Remix Therapeutics and Revolution Medicines; and has research funding from Asana, AstraZeneca, Lilly, Novartis and Sanofi. B.D.G. is a consultant for or received honoraria from Darwin Health, Merck, PMV Pharma, ROME Therapeutics, Merck, Bristol Meyers Squibb and Chugai Pharmaceuticals; is a founder and has equity in ROME Therapeutics; and has research funding from Bristol Meyers Squibb. D.T.T. is a consultant and/or advisory board member for Pfizer, ROME Therapeutics, Merrimack Pharmaceuticals, Ventana Roche, NanoString Technologies, Foundation Medicine, EMD MilliporeSigma and Third Rock Ventures, which are not related to this work; is a founder and has equity in PanTher Therapeutics, ROME Therapeutics and TellBio, which are not related to this work; and has research funding from ACD-Biotechne, PureTech Health and Ribon Therapeutics, which was not used in this work. D.T.T.‘s interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. T.S.H. is consultant and/or advisory board member for Merck, EMD Serono, PanTher Therapeutics, Boston Scientific, Novocure and Synthetic Biologics; and has research funding from Taiho, AstraZeneca, Bristol Myers Squibb, IntraOp, Puma and Ipsen. All other authors have no disclosures.